Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Astellas Pharma Inc. (ALPMY) and partner Toa Eiyo Ltd. recently announced the receipt of marketing approval for their transdermal patch Bisono Tape (4 mg and 8 mg) in Japan.

Bisono Tape, a patch of β1 blocker, is a hypertension medication containing 4 mg or 8 mg of bisoprolol.

The approval was based on phase III studies that showed continuous antihypertensive effects over a period of 24 hours in Japanese mild-to-moderate essential hypertensive patients.

Toa Eiyo and Nitto Denko Corp. co-developed Bisono Tape. Astellas will be responsible for distributing and selling the product, following the Japanese approval. Astellas and Toa Eiyo will co-promote the product.

The hypertension market in Japan is crowded with products like Avapro, Aimix and Azilva receiving marketing approval on Mar 19, 2013, Sep 28, 2012 and Jan 18, 2012 respectively.

We note that Astellas was also in the news recently when it gained Japanese approval of Prograf capsules for interstitial pneumonia associated with polymyositis/dermatomyositis. The drug enjoys orphan status in Japan.

Astellas carries a Zacks Rank #4 (Sell) reflecting short-term pressure on the stock. The bearish rank is primarily attributable to the setback suffered by the company regarding its oncology candidate tivozanib. Astellas recently received a complete response letter (CRL) for tivozanib from the US Food and Drug Administration (FDA) for the advanced renal cell carcinoma indication. The New Drug Application (NDA) was submitted in Sep 2012. The FDA, while issuing the CRL, declined to approve the NDA in its present form.

Right now, companies like Santarus, Inc. , Salix Pharmaceuticals Ltd. (SLXP - Analyst Report)  and Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%